Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Fahim

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
World Journal of Clinical Pediatrics|March 26, 2026
Neonatal cholestasis is associated with cytochrome P450 1A2 detoxification defect: A single center pilot studyMagd A Kotb, Manal M Wilson, Amani N Shafik, et al.
BMC Public Health|December 11, 2012
The efficacy and safety of a nicotine conjugate vaccine (NicVAX®) or placebo co-administered with varenicline (Champix®) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trialPhilippe H J Hoogsteder, Daniel Kotz, Paul I van Spiegel, et al.
Human Vaccines & Immunotherapeutics|December 25, 2016
Safety and immunogenicity of a recombinant Staphylococcus aureus α-toxoid and a recombinant Panton-Valentine leukocidin subunit, in healthy adultsMichael L Landrum, Tahaniyat Lalani, Minoo Niknian, et al.
Clinical Pharmacology and Therapeutics|January 29, 2011
Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeuticD K Hatsukami, D E Jorenby, D Gonzales, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
World Journal of Clinical Pediatrics|March 26, 2026
Neonatal cholestasis is associated with cytochrome P450 1A2 detoxification defect: A single center pilot studyMagd A Kotb, Manal M Wilson, Amani N Shafik, et al.
BMC Public Health|December 11, 2012
The efficacy and safety of a nicotine conjugate vaccine (NicVAX®) or placebo co-administered with varenicline (Champix®) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trialPhilippe H J Hoogsteder, Daniel Kotz, Paul I van Spiegel, et al.
Human Vaccines & Immunotherapeutics|December 25, 2016
Safety and immunogenicity of a recombinant Staphylococcus aureus α-toxoid and a recombinant Panton-Valentine leukocidin subunit, in healthy adultsMichael L Landrum, Tahaniyat Lalani, Minoo Niknian, et al.
Clinical Pharmacology and Therapeutics|January 29, 2011
Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeuticD K Hatsukami, D E Jorenby, D Gonzales, et al.
Pageof 2